(INCY) Incyte - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45337C1027
Stock: Cancer Therapies, Dermatology Treatments, Hematology Drugs
Total Rating 69
Risk 88
Buy Signal -0.29
| Risk 5d forecast | |
|---|---|
| Volatility | 34.8% |
| Relative Tail Risk | -10.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.01 |
| Alpha | 16.67 |
| Character TTM | |
|---|---|
| Beta | 0.685 |
| Beta Downside | 1.116 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.83% |
| CAGR/Max DD | 0.28 |
EPS (Earnings per Share)
Revenue
Description: INCY Incyte March 05, 2026
Incyte Corporation (INCY) is a biopharmaceutical company focused on developing and commercializing therapeutic products. The company operates in the United States, Europe, Canada, and Japan.
INCYs product portfolio includes treatments for various hematologic and oncologic conditions. Key products address myelofibrosis, polycythemia vera, chronic myeloid leukemia, and diffuse large B-cell lymphoma. The company also has a pipeline of clinical-stage assets targeting indications such as ovarian cancer, solid tumors, and inflammatory conditions like atopic dermatitis. Biopharmaceutical companies typically invest heavily in research and development, with a long product development cycle.
The company distributes its products through specialty and retail pharmacies, hospital pharmacies, and distributors. Collaboration and licensing agreements, such as those with Novartis, Lilly, and Syndax, are common in the pharmaceutical industry to share development costs and expand market reach. For a deeper dive into INCYs financial health and market position, consider exploring ValueRays comprehensive analytics.
Headlines to watch out for
- JAKAFI sales drive majority of Incytes revenue
- New drug approvals expand oncology product portfolio
- Clinical trial results impact pipeline valuation
- Competition from generic drugs erodes market share
- Regulatory decisions affect drug commercialization timelines
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 15.15 > 1.0 |
| NWC/Revenue: 68.25% < 20% (prev 37.66%; Δ 30.59% < -1%) |
| CFO/TA 0.20 > 3% & CFO 1.41b > Net Income 1.29b |
| Net Debt (-3.03b) to EBITDA (1.76b): -1.72 < 3 |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (204.8m) vs 12m ago 3.72% < -2% |
| Gross Margin: 91.80% > 18% (prev 0.91%; Δ 9.09k % > 0.5%) |
| Asset Turnover: 82.91% > 50% (prev 77.90%; Δ 5.01% > 0%) |
| Interest Coverage Ratio: 686.5 > 6 (EBITDA TTM 1.76b / Interest Expense TTM 2.43m) |
Altman Z'' 5.35
| A: 0.50 (Total Current Assets 5.02b - Total Current Liabilities 1.52b) / Total Assets 6.96b |
| B: 0.03 (Retained Earnings 213.8m / Total Assets 6.96b) |
| C: 0.27 (EBIT TTM 1.67b / Avg Total Assets 6.20b) |
| D: 0.13 (Book Value of Equity 239.4m / Total Liabilities 1.80b) |
| Altman-Z'' Score: 5.35 = AAA |
Beneish M -3.11
| DSRI: 0.99 (Receivables 1.02b/853.2m, Revenue 5.14b/4.24b) |
| GMI: 0.99 (GM 91.80% / 91.09%) |
| AQI: 0.65 (AQ_t 0.17 / AQ_t-1 0.26) |
| SGI: 1.21 (Revenue 5.14b / 4.24b) |
| TATA: -0.02 (NI 1.29b - CFO 1.41b) / TA 6.96b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of INCY shares?
As of March 13, 2026, the stock is trading at USD 94.66 with a total of 1,726,241 shares traded.
Over the past week, the price has changed by -4.25%, over one month by -4.23%, over three months by -1.50% and over the past year by +39.06%.
Over the past week, the price has changed by -4.25%, over one month by -4.23%, over three months by -1.50% and over the past year by +39.06%.
Is INCY a buy, sell or hold?
Incyte has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold INCY.
- StrongBuy: 8
- Buy: 3
- Hold: 15
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the INCY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 108.8 | 14.9% |
| Analysts Target Price | 108.8 | 14.9% |
INCY Fundamental Data Overview March 12, 2026
P/E Trailing = 15.4003
P/E Forward = 12.7714
P/S = 3.7676
P/B = 3.8066
P/EG = 0.3444
Revenue TTM = 5.14b USD
EBIT TTM = 1.67b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 40.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 69.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.03b USD (from netDebt column, last quarter)
Enterprise Value = 15.86b USD (19.37b + Debt 69.4m - CCE 3.58b)
Interest Coverage Ratio = 686.5 (Ebit TTM 1.67b / Interest Expense TTM 2.43m)
EV/FCF = 11.71x (Enterprise Value 15.86b / FCF TTM 1.35b)
FCF Yield = 8.54% (FCF TTM 1.35b / Enterprise Value 15.86b)
FCF Margin = 26.35% (FCF TTM 1.35b / Revenue TTM 5.14b)
Net Margin = 25.03% (Net Income TTM 1.29b / Revenue TTM 5.14b)
Gross Margin = 91.80% ((Revenue TTM 5.14b - Cost of Revenue TTM 421.6m) / Revenue TTM)
Gross Margin QoQ = 90.88% (prev 92.75%)
Tobins Q-Ratio = 2.28 (Enterprise Value 15.86b / Total Assets 6.96b)
Interest Expense / Debt = 0.84% (Interest Expense 582k / Debt 69.4m)
Taxrate = 23.25% (90.7m / 389.9m)
NOPAT = 1.28b (EBIT 1.67b * (1 - 23.25%))
Current Ratio = 3.32 (Total Current Assets 5.02b / Total Current Liabilities 1.52b)
Debt / Equity = 0.01 (Debt 69.4m / totalStockholderEquity, last quarter 5.17b)
Debt / EBITDA = -1.72 (Net Debt -3.03b / EBITDA 1.76b)
Debt / FCF = -2.24 (Net Debt -3.03b / FCF TTM 1.35b)
Total Stockholder Equity = 4.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.75% (Net Income 1.29b / Total Assets 6.96b)
RoE = 29.15% (Net Income TTM 1.29b / Total Stockholder Equity 4.41b)
RoCE = 37.42% (EBIT 1.67b / Capital Employed (Equity 4.41b + L.T.Debt 40.4m))
RoIC = 28.98% (NOPAT 1.28b / Invested Capital 4.41b)
WACC = 8.38% (E(19.37b)/V(19.44b) * Re(8.41%) + D(69.4m)/V(19.44b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.84%
[DCF] Terminal Value 70.32% ; FCFF base≈906.8m ; Y1≈644.6m ; Y5≈344.8m
[DCF] Fair Price = 46.14 (EV 6.15b - Net Debt -3.03b = Equity 9.18b / Shares 199.0m; r=8.38% [WACC]; 5y FCF grow -33.99% → 2.90% )
EPS Correlation: 28.31 | EPS CAGR: 37.19% | SUE: -0.38 | # QB: 0
Revenue Correlation: 90.88 | Revenue CAGR: 21.18% | SUE: 3.48 | # QB: 6
EPS next Quarter (2026-06-30): EPS=1.79 | Chg7d=+0.009 | Chg30d=-0.175 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=7.42 | Chg7d=+0.000 | Chg30d=-0.544 | Revisions Net=-6 | Growth EPS=+9.1% | Growth Revenue=+8.9%
EPS next Year (2027-12-31): EPS=8.68 | Chg7d=-0.015 | Chg30d=-0.268 | Revisions Net=-2 | Growth EPS=+17.0% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.75 (1 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.9% (Discount Rate 8.4% - Earnings Yield 6.5%)
[Growth] Growth Spread = +11.4% (Analyst 13.3% - Implied 1.9%)
P/E Forward = 12.7714
P/S = 3.7676
P/B = 3.8066
P/EG = 0.3444
Revenue TTM = 5.14b USD
EBIT TTM = 1.67b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 40.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 69.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.03b USD (from netDebt column, last quarter)
Enterprise Value = 15.86b USD (19.37b + Debt 69.4m - CCE 3.58b)
Interest Coverage Ratio = 686.5 (Ebit TTM 1.67b / Interest Expense TTM 2.43m)
EV/FCF = 11.71x (Enterprise Value 15.86b / FCF TTM 1.35b)
FCF Yield = 8.54% (FCF TTM 1.35b / Enterprise Value 15.86b)
FCF Margin = 26.35% (FCF TTM 1.35b / Revenue TTM 5.14b)
Net Margin = 25.03% (Net Income TTM 1.29b / Revenue TTM 5.14b)
Gross Margin = 91.80% ((Revenue TTM 5.14b - Cost of Revenue TTM 421.6m) / Revenue TTM)
Gross Margin QoQ = 90.88% (prev 92.75%)
Tobins Q-Ratio = 2.28 (Enterprise Value 15.86b / Total Assets 6.96b)
Interest Expense / Debt = 0.84% (Interest Expense 582k / Debt 69.4m)
Taxrate = 23.25% (90.7m / 389.9m)
NOPAT = 1.28b (EBIT 1.67b * (1 - 23.25%))
Current Ratio = 3.32 (Total Current Assets 5.02b / Total Current Liabilities 1.52b)
Debt / Equity = 0.01 (Debt 69.4m / totalStockholderEquity, last quarter 5.17b)
Debt / EBITDA = -1.72 (Net Debt -3.03b / EBITDA 1.76b)
Debt / FCF = -2.24 (Net Debt -3.03b / FCF TTM 1.35b)
Total Stockholder Equity = 4.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.75% (Net Income 1.29b / Total Assets 6.96b)
RoE = 29.15% (Net Income TTM 1.29b / Total Stockholder Equity 4.41b)
RoCE = 37.42% (EBIT 1.67b / Capital Employed (Equity 4.41b + L.T.Debt 40.4m))
RoIC = 28.98% (NOPAT 1.28b / Invested Capital 4.41b)
WACC = 8.38% (E(19.37b)/V(19.44b) * Re(8.41%) + D(69.4m)/V(19.44b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -4.84%
[DCF] Terminal Value 70.32% ; FCFF base≈906.8m ; Y1≈644.6m ; Y5≈344.8m
[DCF] Fair Price = 46.14 (EV 6.15b - Net Debt -3.03b = Equity 9.18b / Shares 199.0m; r=8.38% [WACC]; 5y FCF grow -33.99% → 2.90% )
EPS Correlation: 28.31 | EPS CAGR: 37.19% | SUE: -0.38 | # QB: 0
Revenue Correlation: 90.88 | Revenue CAGR: 21.18% | SUE: 3.48 | # QB: 6
EPS next Quarter (2026-06-30): EPS=1.79 | Chg7d=+0.009 | Chg30d=-0.175 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=7.42 | Chg7d=+0.000 | Chg30d=-0.544 | Revisions Net=-6 | Growth EPS=+9.1% | Growth Revenue=+8.9%
EPS next Year (2027-12-31): EPS=8.68 | Chg7d=-0.015 | Chg30d=-0.268 | Revisions Net=-2 | Growth EPS=+17.0% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.75 (1 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.9% (Discount Rate 8.4% - Earnings Yield 6.5%)
[Growth] Growth Spread = +11.4% (Analyst 13.3% - Implied 1.9%)